Metabolic Insights: the Impact of F-18 FDG PET/CT in Adult Lymphoma

PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy

NCT01666353 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)

NCT01004718 ·Status: COMPLETED ·Phase: NA

Hybrid PET/CT in Cancer Patients

NCT00396916 ·Status: COMPLETED ·Phase: NA

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

NCT01410630 ·Status: COMPLETED

Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT

NCT04464590 ·Status: COMPLETED

Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma

NCT00110006 ·Status: WITHDRAWN ·Phase: NA

Usefulness of 18F-FDG PET/CT in the Initial Staging and Surveillance of Endometrial Cancer Patients

NCT05056259 ·Status: UNKNOWN

The Role of 18F-FDG-PET/CT Scan in Lung Cancer Patients

NCT04395651 ·Status: UNKNOWN

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

NCT00757549 ·Status: COMPLETED ·Phase: EARLY_PHASE1

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

NCT02149173 ·Status: TERMINATED ·Phase: NA

Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

NCT00433433 ·Status: UNKNOWN ·Phase: PHASE3

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

NCT04316117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma

NCT00775957 ·Status: TERMINATED

Evaluating the Usefulness of 18F-AlF-FAPI PET/ CT in Orbital Neoplasms

NCT06791226 ·Status: RECRUITING ·Phase: NA

MRI Compared to PET/CT for Staging and Treatment Response in Lymphoma

NCT02733887 ·Status: UNKNOWN ·Phase: NA

Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer

NCT01627704 ·Status: COMPLETED ·Phase: NA

Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide

NCT03065790 ·Status: TERMINATED

FDG PET/CT and Directed Metabolic Core Needle Biopsy in the Management of Lymphoma

NCT05186610 ·Status: COMPLETED

A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation

NCT00847509 ·Status: COMPLETED ·Phase: NA

Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality

NCT02378337 ·Status: COMPLETED

Role of Positron Emission Tomography/ Computed Tomography (PET/CT) and in Bone Metastases.

NCT04080271 ·Status: COMPLETED

Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

NCT00678327 ·Status: COMPLETED ·Phase: PHASE3

Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT

NCT05614518 ·Status: COMPLETED ·Phase: PHASE3

Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma

NCT03262389 ·Status: COMPLETED ·Phase: PHASE2

Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma

NCT00915096 ·Status: COMPLETED